Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease.

RATIONALE Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening. OBJECTIVES To assess SAA as a biomarker of AECOPD. METHODS Biomarkers were assessed (1) cross-sectionally (stable vs. AECOPD; 62 individuals) and (2) longitudinally with repeated measures (baseline vs. AECOPD vs. convalescence; 78 episodes in 37 individuals). Event severity was graded (I, ambulatory; II, hospitalized; III, respiratory failure) based on consensus guidelines. MEASUREMENTS AND MAIN RESULTS Presumptively newly acquired pathogens were associated with onset of symptomatic AECOPD. In the cross-sectional study, both SAA and C-reactive protein (CRP) were elevated at AECOPD onset compared with stable disease (SAA median, 7.7 vs. 57.6 mg/L; P < 0.01; CRP median, 4.6 vs. 12.5 mg/L; P < 0.01). Receiver operator characteristics analysis was used to generate area-under-curve values for event severity. SAA discriminated level II/III events (SAA, 0.88; 95% confidence interval, 0.80-0.94 vs. CRP, 0.80; 95% confidence interval, 0.70-0.87; P = 0.05). Combining SAA or CRP with major symptoms (Anthonisen criteria, dyspnea) did not further improve the prediction model for severe episodes. IL-6 and procalcitonin were not informative. CONCLUSIONS SAA is a novel blood biomarker of AECOPD that is more sensitive than CRP alone or in combination with dyspnea. SAA may offer new insights into the pathogenesis of AECOPD.

[1]  J. Bylund,et al.  Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7‐sensitive pathway independent of formyl peptide receptor‐like 1 , 2008, Journal of leukocyte biology.

[2]  A. Lowe,et al.  A community-based, time-matched, case-control study of respiratory viruses and exacerbations of COPD. , 2007, Respiratory medicine.

[3]  J. Rehfeld,et al.  Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.

[4]  S. Johnston,et al.  IFN-γ–induced protein 10 is a novel biomarker of rhinovirus-induced asthma exacerbations , 2007, Journal of Allergy and Clinical Immunology.

[5]  Bartolome Celli,et al.  Profiling serum biomarkers in patients with COPD: associations with clinical parameters , 2007, Thorax.

[6]  B. Celli,et al.  Exacerbations of chronic obstructive pulmonary disease , 2007, European Respiratory Journal.

[7]  J. Struck,et al.  Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. , 2007, Chest.

[8]  H. Valadi,et al.  Functional relevance of the IL-23-IL-17 axis in lungs in vivo. , 2007, American journal of respiratory cell and molecular biology.

[9]  D. Curran‐Everett,et al.  IL4Rα Mutations Are Associated with Asthma Exacerbations and Mast Cell/IgE Expression , 2007 .

[10]  A. Bergmann,et al.  Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections , 2007, European journal of clinical investigation.

[11]  S. Bojesen,et al.  C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[12]  B. Celli,et al.  Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. , 2007, Chest.

[13]  M. Cazzola,et al.  Markers of exacerbation severity in chronic obstructive pulmonary disease. , 2006, Respiratory research.

[14]  John R Hurst,et al.  Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[15]  N. Anthonisen,et al.  C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease , 2006, Thorax.

[16]  J. Raynes,et al.  Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. , 2006, Blood.

[17]  S. Johnston,et al.  Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. , 2006, American journal of respiratory and critical care medicine.

[18]  R. Stockley,et al.  COPD exacerbations · 2: Aetiology , 2006, Thorax.

[19]  S. Harbo,et al.  Gene Expression Profiling in Lung Tissues from Mice Exposed to Cigarette Smoke, Lipopolysaccharide, or Smoke Plus Lipopolysaccharide by Inhalation , 2006, Inhalation toxicology.

[20]  J. Soriano,et al.  C-reactive protein in patients with COPD, control smokers and non-smokers , 2005, Thorax.

[21]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[22]  J. Wedzicha,et al.  Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[23]  T. Seemungal,et al.  Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD , 2005, Chest.

[24]  R. Rodríguez-Roisín.  Is this the beginning of unravelling the puzzle of COPD exacerbations? , 2005, European Respiratory Journal.

[25]  David E. Misek,et al.  Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis , 2005, BMC Cancer.

[26]  M. Parnham,et al.  Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. , 2005, European journal of pharmacology.

[27]  M. Lenter,et al.  Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface‐enhanced laser desorption/ionization‐mass spectrometry profiling with mass spectrometric protein identification , 2005, Proteomics.

[28]  H. Kelly,et al.  Laboratory diagnosis and surveillance of human respiratory viruses by PCR in Victoria, Australia, 2002–2003 , 2004, Journal of medical virology.

[29]  Zheng Wang,et al.  Protein Chip Array Profiling Analysis in Patients with Severe Acute Respiratory Syndrome Identified Serum Amyloid A Protein as a Biomarker Potentially Useful in Monitoring the Extent of Pneumonia , 2004, Clinical chemistry.

[30]  R. Schleimer,et al.  Activation of airway epithelial cells by toll-like receptor agonists. , 2004, American journal of respiratory cell and molecular biology.

[31]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[32]  B. Bresnihan,et al.  Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. , 2004, Arthritis and rheumatism.

[33]  M. Christ-Crain,et al.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial , 2004, The Lancet.

[34]  S. Reis,et al.  Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women: The National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation (WISE) , 2004, Circulation.

[35]  C. Thorn,et al.  Regulation of the Human Acute Phase Serum Amyloid A Genes by Tumour Necrosis Factor‐α, Interleukin‐6 and Glucocorticoids in Hepatic and Epithelial Cell Lines , 2004, Scandinavian journal of immunology.

[36]  M. Cassatella,et al.  mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. , 2003, Mediators of inflammation.

[37]  D. Sin,et al.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. , 2003, Circulation.

[38]  Development of a predictive index for picornavirus infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  K. Nichol,et al.  Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  A. Gillissen,et al.  Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study , 2003, Thorax.

[41]  J. Sterne,et al.  Essential Medical Statistics , 2003 .

[42]  T. Seemungal,et al.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.

[43]  S. Sethi.  Bacterial pneumonia. Managing a deadly complication of influenza in older adults with comorbid disease. , 2002, Geriatrics.

[44]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[45]  E. Walsh,et al.  Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. , 2001, The Journal of infectious diseases.

[46]  K. Wright,et al.  Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[47]  S. Ramsey,et al.  The economic burden of COPD. , 2000, Chest.

[48]  G. Boivin,et al.  Predicting influenza infections during epidemics with use of a clinical case definition. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  R. Stockley,et al.  Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. , 2000, Chest.

[50]  R. Rodríguez-Roisín,et al.  Toward a consensus definition for COPD exacerbations. , 2000, Chest.

[51]  R. Badolato,et al.  Serum amyloid A is an activator of PMN antimicrobial functions: induction of degranulation, phagocytosis, and enhancement of anti‐Candida activity , 2000, Journal of leukocyte biology.

[52]  S. Urieli-Shoval,et al.  Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states , 2000, Current opinion in hematology.

[53]  P. Ridker,et al.  C-reactive protein, inflammation, and coronary risk. , 2000, The Medical clinics of North America.

[54]  C. Lavie,et al.  Benefits of cardiac rehabilitation and exercise training. , 2000, Chest.

[55]  K. Migita,et al.  Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[56]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[57]  J. Govan,et al.  Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. , 1998, Respiratory medicine.

[58]  J. Rotter,et al.  Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. , 1997, Circulation.

[59]  J. Schwartz,et al.  Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. , 1997, The European respiratory journal.

[60]  A. Whitehead,et al.  Expression and Regulation of Constitutive and Acute Phase Serum Amyloid A mRNAs in Hepatic and Non‐Hepatic Cell Lines , 1996, Scandinavian journal of immunology.

[61]  F. D. de Beer,et al.  Human serum amyloid A (SAA) protein: a prominent acute‐phase reactant for clinical practice , 1996, European journal of clinical investigation.

[62]  T. Lee.  Lipoxin A4: a novel anti-inflammatory molecule? , 1995, Thorax.

[63]  R. Badolato,et al.  Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes , 1994, The Journal of experimental medicine.

[64]  N. Anthonisen,et al.  Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.

[65]  F. D. de Beer,et al.  Acute phase response in bronchiectasis and bronchus carcinoma. , 1984, Respiration; international review of thoracic diseases.